<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551252</url>
  </required_header>
  <id_info>
    <org_study_id>GIMe/01/06</org_study_id>
    <nct_id>NCT00551252</nct_id>
  </id_info>
  <brief_title>A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma</brief_title>
  <official_title>A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano MEsotelioma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano MEsotelioma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antitumor activity of a combination of Imatinib&#xD;
      mesylate and Gemcitabine in patients with unresectable malignant mesothelioma expressing&#xD;
      either PDGFR-beta or C-kit&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TITLE &quot;A phase II study of the association of Glivec® (Imatinib mesylate, formerly known as&#xD;
      STI 571) plus Gemzar® (Gemcitabine) in patients with unresectable, refractory, malignant&#xD;
      mesothelioma expressing either PDGFR-beta or C-Kit&quot;&#xD;
&#xD;
      PURPOSE Primary objective of the phase II&#xD;
&#xD;
      &gt; Efficacy, i.e., response rate to study drugs&#xD;
&#xD;
      Secondary objectives of the phase II&#xD;
&#xD;
        -  Duration of response&#xD;
&#xD;
        -  Time to progression&#xD;
&#xD;
        -  Toxicity profile&#xD;
&#xD;
        -  Overall survival&#xD;
&#xD;
      PRIMARY VARIABLE The primary efficacy variable for the phase II part of the study is Best&#xD;
      Overall Tumor Response, evaluated using the &quot;Modified RECIST criteria for assessment of&#xD;
      response in malignant pleural mesothelioma&quot;&#xD;
&#xD;
      SECONDARY VARIABLES&#xD;
&#xD;
        -  Progression-free survival (PFS) form 1st administration onwards&#xD;
&#xD;
        -  Overall survival&#xD;
&#xD;
        -  Safety criteria, according to NCI-CTC criteria version 3.0&#xD;
&#xD;
      EFFICACY Objective tumor response assesed using the &quot;Modified RECIST criteria for assessment&#xD;
      of response in malignant pleural mesothelioma&quot; SAFETY&#xD;
&#xD;
        -  Adverse events&#xD;
&#xD;
        -  Vital signs&#xD;
&#xD;
        -  Clinical and biohumoral findings&#xD;
&#xD;
      TREATMENT SCHEDULE&#xD;
&#xD;
        -  Gemzar 500 mg/m2, i.v., days 1 and 8 of a 21-days schedule, plus&#xD;
&#xD;
        -  Glivec 400 mg/die., per os&#xD;
&#xD;
      STATISTICAL DESIGN The study follows a two-stage design, according to the Simon model. We&#xD;
      assume that with a response rate of 5% (H0) or less the drug is likely to be ineffective, and&#xD;
      also, that, for the drug to be effective, a target response rate of 15% (H1) is required.&#xD;
      With a probability errors alfa of 5% and beta 20%, the calculated sample size is as reported&#xD;
      in &quot;PLANNED NUMBER OF PTS.&quot;&#xD;
&#xD;
      PLANNED NUMBER OF PTS. 23 or 56 patients, evaluable for efficacy. The number depends on the&#xD;
      response rate. When 2 or more objective responses, i.e., CR or PR, are observed in the first&#xD;
      23 patients, the total number of patients will be increased to 56, otherwise the study will&#xD;
      be stopped&#xD;
&#xD;
      STATISTICAL EVALUATION Efficacy and safety variables will be evaluated descriptively. Indeed,&#xD;
      ORR estimates and its exact 95% confidence interval will be calculated. Kaplan-Meier method&#xD;
      will be used to estimate duration of response, PFS and OS&#xD;
&#xD;
      DURATION OF TREATMENT All patients are scheduled to receive at least two cycles of&#xD;
      chemotherapy unless there is unacceptable toxicity, progressive disease, or the patient&#xD;
      requires or asks for withdrawal from the study Responding patients will receive treatment for&#xD;
      6 cycles or earlier if progression or unbearable toxicity Disease status will be re-evaluated&#xD;
      every two cycles, using the same imaging procedures used at baseline, i.e., CT or NMR&#xD;
&#xD;
      INCLUSION CRITERIA&#xD;
&#xD;
        -  Age of &gt; 18 years and &lt; 72 years&#xD;
&#xD;
        -  Patients with a histologically proven malignant mesothelioma of the pleura or of the&#xD;
           peritoneum, expressing either PDFGR-beta or C-Kit by immunochemistry (ICH)&#xD;
&#xD;
        -  Locally advanced disease, unsuitable for curative surgical resection, or metastatic&#xD;
           disease&#xD;
&#xD;
        -  Confirmed progression of the disease according to modified REcist-criteria, documented&#xD;
           after a first-line, systemic (premetrex+cisplatin regimen) or local treatment (i.e.,&#xD;
           intrapleuric)&#xD;
&#xD;
        -  ECOG Performance Status of 0, 1 or 2&#xD;
&#xD;
        -  Life expectancy of at least 3 months&#xD;
&#xD;
        -  Capability of understanding the objectives of the study and giving written informed&#xD;
           consent&#xD;
&#xD;
        -  Willingness and ability to comply with study requirements&#xD;
&#xD;
        -  Sufficient caloric and fluid intake, including patients under enteral or parenteral&#xD;
           nutrition&#xD;
&#xD;
      EXCLUSION CRITERIA&#xD;
&#xD;
        -  Co-existing tumors of different histologic origin, except non melanomatous localized&#xD;
           skin cancer and/or in situ cervical carcinoma&#xD;
&#xD;
        -  A history of earlier tumors of different histologic origin being in complete remission&#xD;
           since less than 5 years&#xD;
&#xD;
        -  Unresolved toxicity from prior antitumor treatment(s)&#xD;
&#xD;
        -  Primary peritoneal mesothelioma&#xD;
&#xD;
        -  Any of the following abnormal baseline hematological values:&#xD;
&#xD;
             -  Hb &lt; 9 g/dL&#xD;
&#xD;
             -  WBC &lt; 3 x 109/L&#xD;
&#xD;
             -  Neutrophils &lt; 1.5 x 109/L&#xD;
&#xD;
             -  Platelets &lt; 100 x 109/L&#xD;
&#xD;
             -  Serum bilirubin &gt; 2.5 mg/dL&#xD;
&#xD;
             -  ALAT and ASAT &gt; 3 x UNL (unless due to liver metastases)&#xD;
&#xD;
             -  Serum creatinine &gt; 1.5 mg/dL&#xD;
&#xD;
        -  Clinically relevant cardiovascular disease, i.e., myocardial infarction or other severe&#xD;
           coronary artery diseases within the prior 6 months, cardiac arrythmia requiring&#xD;
           medication, uncontrolled hypertension, overt cardiac failure or non compensated chronic&#xD;
           heart disease in NYHA class II or more&#xD;
&#xD;
        -  History of psychiatric disabilities, potentially interfering with the capability of&#xD;
           giving adequate informed consent&#xD;
&#xD;
        -  Pregnant or lactating women or inability/unwillingness to practice a medically approved&#xD;
           method of contraception during study period (including 3 months following the end of&#xD;
           treatment)&#xD;
&#xD;
        -  Uncontrolled active infections&#xD;
&#xD;
        -  Any condition which, in the judgement of the Investigator, would place the patient at&#xD;
           undue risk or interfere with the results of the study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Every two months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free-survival; Overall Survival; Safety</measure>
    <time_frame>Follow-up after end of treatment will be every three months; safety will be analyzed throughout the whole study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate plus Gemcitabine</intervention_name>
    <description>Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of &gt; 18 years and &lt; 72 years&#xD;
&#xD;
          -  Patients with a histologically proven malignant mesothelioma of the pleura or of the&#xD;
             peritoneum, expressing either PDFGR-beta or C-Kit by immunochemistry (ICH)&#xD;
&#xD;
          -  Locally advanced disease, unsuitable for curative surgical resection, or metastatic&#xD;
             disease&#xD;
&#xD;
          -  Confirmed progression of the disease according to modified REcist-criteria, documented&#xD;
             after a first-line, systemic (premetrex+cisplatin regimen) or local treatment (i.e.,&#xD;
             intrapleuric)&#xD;
&#xD;
          -  ECOG Performance Status of 0, 1 or 2&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Capability of understanding the objectives of the study and giving written informed&#xD;
             consent&#xD;
&#xD;
          -  Willingness and ability to comply with study requirements&#xD;
&#xD;
          -  Sufficient caloric and fluid intake, including patients under enteral or parenteral&#xD;
             nutrition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-existing tumors of different histologic origin, except non melanomatous localized&#xD;
             skin cancer and/or in situ cervical carcinoma&#xD;
&#xD;
          -  A history of earlier tumors of different histologic origin being in complete remission&#xD;
             since less than 5 years&#xD;
&#xD;
          -  Unresolved toxicity from prior antitumor treatment(s)&#xD;
&#xD;
          -  Primary peritoneal mesothelioma&#xD;
&#xD;
          -  Any of the following abnormal baseline hematological values:&#xD;
&#xD;
               -  Hb &lt; 9 g/dL&#xD;
&#xD;
               -  WBC &lt; 3 x 109/L&#xD;
&#xD;
               -  Neutrophils &lt; 1.5 x 109/L&#xD;
&#xD;
               -  Platelets &lt; 100 x 109/L&#xD;
&#xD;
               -  Serum bilirubin &gt; 2.5 mg/dL&#xD;
&#xD;
               -  ALAT and ASAT &gt; 3 x UNL (unless due to liver metastases)&#xD;
&#xD;
               -  Serum creatinine &gt; 1.5 mg/dL&#xD;
&#xD;
          -  Clinically relevant cardiovascular disease, i.e., myocardial infarction or other&#xD;
             severe coronary artery diseases within the prior 6 months, cardiac arrythmia requiring&#xD;
             medication, uncontrolled hypertension, overt cardiac failure or non compensated&#xD;
             chronic heart disease in NYHA class II or more&#xD;
&#xD;
          -  History of psychiatric disabilities, potentially interfering with the capability of&#xD;
             giving adequate informed consent&#xD;
&#xD;
          -  Pregnant or lactating women or inability/unwillingness to practice a medically&#xD;
             approved method of contraception during study period (including 3 months following the&#xD;
             end of treatment)&#xD;
&#xD;
          -  Uncontrolled active infections&#xD;
&#xD;
          -  Any condition which, in the judgement of the Investigator, would place the patient at&#xD;
             undue risk or interfere with the results of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camillo Porta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncology, IRCCS San Matteo University Hospital Foundation, pavia, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camillo Porta, MD</last_name>
    <phone>+39-0382-501355</phone>
    <email>c.porta@smatteo.pv.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Oncology, IRCCS San Matteo University Hospital Foundation</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <investigator>
      <last_name>Camillo Porta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gime.it</url>
    <description>Italian Mesothelioma Group Homepage</description>
  </link>
  <reference>
    <citation>Bertino P, Porta C, Barbone D, Germano S, Busacca S, Pinato S, Tassi G, Favoni R, Gaudino G, Mutti L. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax. 2007 Aug;62(8):690-5. Epub 2007 Feb 20.</citation>
    <PMID>17311837</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>October 29, 2007</study_first_submitted>
  <study_first_submitted_qc>October 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <last_update_submitted>October 29, 2007</last_update_submitted>
  <last_update_submitted_qc>October 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

